A Single-Center Phase Ha Study Evaluating the Safety and Tolerability of Umbralisib and Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Lunning Matthew A.; Bierman Philip; Bociek R. Gregory; Armitage James O.; Heires Peggy; Hohenstein Maribeth; Blumel Susan; Tefft Jonathan; Lyden Elizabeth R.; Green Michael R.; Vose Julie M.

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >A Single-Center Phase Ha Study Evaluating the Safety and Tolerability of Umbralisib and Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

【24h】

A Single-Center Phase Ha Study Evaluating the Safety and Tolerability of Umbralisib and Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

机译：单级相HA研究评估umbralisib和伊布洛尼布在复发或难治性弥漫性大B细胞淋巴瘤患者中的安全性和耐受性

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2018年第novaelatreatmentappr期|共2页
作者
Lunning Matthew A.; Bierman Philip; Bociek R. Gregory; Armitage James O.; Heires Peggy; Hohenstein Maribeth; Blumel Susan; Tefft Jonathan; Lyden Elizabeth R.; Green Michael R.; Vose Julie M.;
展开▼
作者单位

Univ Nebraska Med Ctr Omaha NE USA;

Univ Nebraska Med Ctr Omaha NE USA;

Univ Nebraska Med Ctr Omaha NE USA;

Univ Nebraska Med Ctr Omaha NE USA;

Univ Nebraska Med Ctr Omaha NE USA;

Univ Nebraska Med Ctr Omaha NE USA;

Univ Nebraska Med Ctr Omaha NE USA;

Univ Nebraska Med Ctr Omaha NE USA;

Univ Nebraska Med Ctr Omaha NE USA;

Univ Nebraska Eppley Inst Res Canc &

Allied Dis Omaha NE 68182 USA;

Univ Nebraska Med Ctr Omaha NE USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
中文文献
专利

1. A Single-Center Phase Ha Study Evaluating the Safety and Tolerability of Umbralisib and Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma [J] . Lunning Matthew A., Bierman Philip, Bociek R. Gregory, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：单级相HA研究评估umbralisib和伊布洛尼布在复发或难治性弥漫性大B细胞淋巴瘤患者中的安全性和耐受性
2. A Multicenter Open-Label, Phase 1b/2 Study of Ibrutinib in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) [J] . Goy Andre, Ramchandren Radhakrishnan, Ghosh Nilanjan, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：复发性或难治性（R / R）弥漫性大B细胞淋巴瘤（DLBCL）患者中依鲁替尼联合来那度胺和利妥昔单抗的多中心开放标签1b / 2期研究
3. A Multicenter Open-Label, Phase 1b/2 Study of Ibrutinib in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) [J] . Goy Andre, Ramchandren Radhakrishnan, Ghosh Nilanjan, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：复发性或难治性（R / R）弥漫性大B细胞淋巴瘤（DLBCL）患者中依鲁替尼联合来那度胺和利妥昔单抗的多中心开放标签1b / 2期研究
4. Mutational profile of Diffuse Large B-cell Lymphoma with central nervous system relapse: analysis of CBioPortal for Cancer Genomics database [C] . Elena Voropaeva, Olga Beresina, Tatyana Pospelova, Conference on Cognitive Sciences, Genomics and Bioinformatics . 2020

机译：弥漫性大B细胞淋巴瘤与中枢神经系统复发的突变特征：用于癌症基因组学数据库的CBioPortal分析
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. A phase I/II trial to evaluate the safety feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma – the STORM trial [O] . Mathias Witzens-Harig, Marie Luise Memmer, Martin Dreyling, 2013

机译：I / II期试验评估挽救疗法的安全性可行性和活性该疗法由mTOR抑制剂Temsirolimus联合利妥昔单抗和DHAP的标准疗法组成用于治疗复发性或难治性弥漫性大细胞B细胞淋巴瘤患者– STORM试用
7. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1–1b study [O] . Matthew S Davids, Haesook T Kim, Alyssa Nicotra, 2019

机译：umbralisib与复发或难治性慢性淋巴细胞白血病或地幔细胞淋巴瘤患者的伊布洛替尼结合：多期第1-1B研究

A Single-Center Phase Ha Study Evaluating the Safety and Tolerability of Umbralisib and Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

著录项

相似文献

相关主题

期刊订阅